FDA approves CTI BioPharma's bone marrow cancer drug | Reuters
CTI BioPharma Corp. (NASDAQ:CTIC) Q4 2022 Earnings Call Transcript
CTI BioPharma | LinkedIn
Struggling CTI reveals new pacritinib data, misses a primary endpoint | Fierce Biotech
Adam Craig - President and Chief Executive Officer - CTI BioPharma Corp. | LinkedIn
CTI BioPharma: Q4, Missed Earnings, But Compelling Progress In Market Launch | Seeking Alpha
Stonepine Capital Management Cuts Stake in CTI BioPharma (CTIC) | Nasdaq
KUOW - 'Bad News' For Seattle Biotech Company As FDA Suspends Drug Trials
CTI Biopharma confirms a CRO is involved in Ph III trial halted after deaths
CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction
Adam Craig - President and Chief Executive Officer - CTI BioPharma Corp. | LinkedIn
CTI BioPharma: A Speculative Buy Into The PDUFA Date (NASDAQ:CTIC) | Seeking Alpha
CTI BioPharma | Targeted Blood Cancer Therapies | Home
CTI BioPharma | Compliance & Transparency
CTI BioPharma | Targeted Blood Cancer Therapies | Home
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial
CTI BioPharma | LinkedIn
CTI BioPharma (CTIC) Investor Presentation - Slideshow (NASDAQ:CTIC) | Seeking Alpha
